# Genitourinary Tumors With Sacituzumab Tirumotecan

> **NCT07716917** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD** · enrollment: 100 (estimated)

## Conditions studied

- Papillary Renal Carcinoma
- Variant Histology Urothelial Carcinoma

## Interventions

- **DRUG:** Sacituzumab Tirumotecan (SKB264)

## Key facts

- **NCT ID:** NCT07716917
- **Lead sponsor:** Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-10
- **Final completion:** 2029-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716917, "Genitourinary Tumors With Sacituzumab Tirumotecan". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*